vs

Side-by-side financial comparison of ESCO TECHNOLOGIES INC (ESE) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

ESCO TECHNOLOGIES INC is the larger business by last-quarter revenue ($289.7M vs $225.6M, roughly 1.3× Organogenesis Holdings Inc.). Organogenesis Holdings Inc. runs the higher net margin — 19.4% vs 9.9%, a 9.5% gap on every dollar of revenue. On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs 17.3%). ESCO TECHNOLOGIES INC produced more free cash flow last quarter ($63.0M vs $34.8M). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs 7.8%).

Esco is a Singaporean brand that develops, manufactures, and sells products and services for laboratories.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

ESE vs ORGO — Head-to-Head

Bigger by revenue
ESE
ESE
1.3× larger
ESE
$289.7M
$225.6M
ORGO
Growing faster (revenue YoY)
ORGO
ORGO
+60.9% gap
ORGO
78.1%
17.3%
ESE
Higher net margin
ORGO
ORGO
9.5% more per $
ORGO
19.4%
9.9%
ESE
More free cash flow
ESE
ESE
$28.2M more FCF
ESE
$63.0M
$34.8M
ORGO
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
7.8%
ESE

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ESE
ESE
ORGO
ORGO
Revenue
$289.7M
$225.6M
Net Profit
$28.7M
$43.7M
Gross Margin
41.4%
Operating Margin
13.2%
28.1%
Net Margin
9.9%
19.4%
Revenue YoY
17.3%
78.1%
Net Profit YoY
22.2%
469.5%
EPS (diluted)
$1.11
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESE
ESE
ORGO
ORGO
Q4 25
$289.7M
$225.6M
Q3 25
$286.5M
$150.9M
Q2 25
$296.3M
$101.0M
Q1 25
$265.5M
$86.7M
Q4 24
$247.0M
$126.7M
Q3 24
$298.5M
$115.2M
Q2 24
$260.8M
$130.2M
Q1 24
$249.1M
$110.0M
Net Profit
ESE
ESE
ORGO
ORGO
Q4 25
$28.7M
$43.7M
Q3 25
$218.7M
$21.6M
Q2 25
$26.1M
$-9.4M
Q1 25
$31.0M
$-18.8M
Q4 24
$23.5M
$7.7M
Q3 24
$34.3M
$12.3M
Q2 24
$29.2M
$-17.0M
Q1 24
$23.2M
$-2.1M
Gross Margin
ESE
ESE
ORGO
ORGO
Q4 25
41.4%
Q3 25
45.9%
Q2 25
41.2%
Q1 25
41.1%
72.6%
Q4 24
39.8%
75.5%
Q3 24
40.1%
76.7%
Q2 24
39.6%
77.6%
Q1 24
38.8%
73.9%
Operating Margin
ESE
ESE
ORGO
ORGO
Q4 25
13.2%
28.1%
Q3 25
17.2%
13.7%
Q2 25
11.2%
-12.5%
Q1 25
15.3%
-30.9%
Q4 24
11.4%
8.1%
Q3 24
14.8%
5.4%
Q2 24
14.3%
-10.7%
Q1 24
11.7%
-3.5%
Net Margin
ESE
ESE
ORGO
ORGO
Q4 25
9.9%
19.4%
Q3 25
76.3%
14.3%
Q2 25
8.8%
-9.3%
Q1 25
11.7%
-21.7%
Q4 24
9.5%
6.1%
Q3 24
11.5%
10.7%
Q2 24
11.2%
-13.1%
Q1 24
9.3%
-1.9%
EPS (diluted)
ESE
ESE
ORGO
ORGO
Q4 25
$1.11
$0.31
Q3 25
$8.43
$0.11
Q2 25
$1.01
$-0.10
Q1 25
$1.20
$-0.17
Q4 24
$0.91
$0.05
Q3 24
$1.32
$0.09
Q2 24
$1.13
$-0.13
Q1 24
$0.90
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESE
ESE
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$103.8M
$93.7M
Total DebtLower is stronger
$145.5M
Stockholders' EquityBook value
$1.6B
$300.1M
Total Assets
$2.4B
$598.7M
Debt / EquityLower = less leverage
0.09×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESE
ESE
ORGO
ORGO
Q4 25
$103.8M
$93.7M
Q3 25
$101.3M
$63.7M
Q2 25
$78.7M
$73.1M
Q1 25
$57.4M
$110.0M
Q4 24
$71.3M
$135.6M
Q3 24
$66.0M
$94.3M
Q2 24
$63.0M
$89.9M
Q1 24
$59.4M
$88.6M
Total Debt
ESE
ESE
ORGO
ORGO
Q4 25
$145.5M
Q3 25
$186.0M
Q2 25
$525.0M
Q1 25
$88.0M
Q4 24
$112.0M
Q3 24
$122.0M
$62.3M
Q2 24
$173.0M
$63.8M
Q1 24
$191.0M
$65.2M
Stockholders' Equity
ESE
ESE
ORGO
ORGO
Q4 25
$1.6B
$300.1M
Q3 25
$1.5B
$255.1M
Q2 25
$1.3B
$233.2M
Q1 25
$1.3B
$242.9M
Q4 24
$1.2B
$262.9M
Q3 24
$1.2B
$278.5M
Q2 24
$1.2B
$263.5M
Q1 24
$1.2B
$278.0M
Total Assets
ESE
ESE
ORGO
ORGO
Q4 25
$2.4B
$598.7M
Q3 25
$2.4B
$509.8M
Q2 25
$2.5B
$461.1M
Q1 25
$1.8B
$467.4M
Q4 24
$1.8B
$497.9M
Q3 24
$1.8B
$446.3M
Q2 24
$1.8B
$443.2M
Q1 24
$1.8B
$458.5M
Debt / Equity
ESE
ESE
ORGO
ORGO
Q4 25
0.09×
Q3 25
0.12×
Q2 25
0.40×
Q1 25
0.07×
Q4 24
0.09×
Q3 24
0.10×
0.22×
Q2 24
0.14×
0.24×
Q1 24
0.16×
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESE
ESE
ORGO
ORGO
Operating Cash FlowLast quarter
$68.9M
$39.4M
Free Cash FlowOCF − Capex
$63.0M
$34.8M
FCF MarginFCF / Revenue
21.7%
15.4%
Capex IntensityCapex / Revenue
2.0%
2.1%
Cash ConversionOCF / Net Profit
2.40×
0.90×
TTM Free Cash FlowTrailing 4 quarters
$239.6M
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESE
ESE
ORGO
ORGO
Q4 25
$68.9M
$39.4M
Q3 25
$109.9M
$3.1M
Q2 25
$73.7M
$-32.9M
Q1 25
$24.1M
$-19.9M
Q4 24
$34.2M
$10.9M
Q3 24
$72.1M
$8.7M
Q2 24
$36.2M
$4.7M
Q1 24
$10.5M
$-10.2M
Free Cash Flow
ESE
ESE
ORGO
ORGO
Q4 25
$63.0M
$34.8M
Q3 25
$97.8M
$844.0K
Q2 25
$64.9M
$-36.5M
Q1 25
$14.0M
$-23.6M
Q4 24
$29.0M
$7.6M
Q3 24
$60.9M
$6.1M
Q2 24
$27.6M
$2.9M
Q1 24
$2.0M
$-12.4M
FCF Margin
ESE
ESE
ORGO
ORGO
Q4 25
21.7%
15.4%
Q3 25
34.1%
0.6%
Q2 25
21.9%
-36.1%
Q1 25
5.3%
-27.2%
Q4 24
11.7%
6.0%
Q3 24
20.4%
5.3%
Q2 24
10.6%
2.2%
Q1 24
0.8%
-11.3%
Capex Intensity
ESE
ESE
ORGO
ORGO
Q4 25
2.0%
2.1%
Q3 25
4.2%
1.5%
Q2 25
3.0%
3.6%
Q1 25
3.8%
4.2%
Q4 24
2.1%
2.7%
Q3 24
3.8%
2.2%
Q2 24
3.3%
1.4%
Q1 24
3.4%
2.0%
Cash Conversion
ESE
ESE
ORGO
ORGO
Q4 25
2.40×
0.90×
Q3 25
0.50×
0.14×
Q2 25
2.83×
Q1 25
0.78×
Q4 24
1.46×
1.43×
Q3 24
2.10×
0.71×
Q2 24
1.24×
Q1 24
0.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESE
ESE

US Government$98.0M34%
Utility Solutions Group$87.5M30%
RF Shielding And Test$58.3M20%
Commercial$45.8M16%
Related Party$1.3M0%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons